Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.

Related Keywords

United States ,American ,Mazyar Shadman ,Fred Hutch Cancer Center ,American Society Of Hematology Annual Meeting ,Hematology Annual Meeting ,Network Endowed Chair ,Cash ,American Society Of Hematology ,B Cell Malignancies ,Zanubrutinib ,